Drugs / ALXN1920
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05751642 | Apr → Dec 2023 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07157787 | Sep 2025 → Jul 2027 expected | idiopathic membranous glomerulonephritis | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN1920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157787 ↗ |
| Route | Subcutaneous | “by Subcutaneous (SC) injection” NCT05751642 ↗ |